{'fraction_non_alphanumeric': 0.03731343283582089, 'fraction_numerical': 0.03171641791044776, 'mean_word_length': 5.244186046511628, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The risk of acquired long QT syndrome during a coronavirus epidemic. Focus on hydroxychloroquine].

Hydroxychloroquine is an immunomodulatory agent used primarily in malaria, lupus erythematosus, and rheumatoid arthritis. The authors summarize the potential proarrhythmic effect of this formulation and the key signs of drug-induced long QT syndrome. The topicality of the present summary is given by the more frequent use of hydroxychloroquine (currently without evidence) in the COVID-19 epidemic. Orv Hetil. 2020; 161 (17): 689-691.